ASCO GU 2022

ASCO GU 2022
February 17-19, 2022
Virtual & San Francisco, CA

American Society of Clinical Oncology Genitourinary Cancers Symposium.

Explore more information for Gilead Oncology therapies
Results (4)

TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.

TROPHY-U-01 Cohort 4

TROPiCS-04: Study of sacituzumab govitecan (SG) in patients (pts) with locally advanced (LA) unresectable or metastatic urothelial cancer (mUC) that has progressed after prior platinum (PLT) and checkpoint inhibitor (CPI) therapy.

A phase 2, multiarm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors